Shot of shelves stocked with various medicinal products in a pharmacy
Our Work

Latham & Watkins Advises CHEPLAPHARM on Investment by Two Global Investors

October 25, 2022
Latham represents CHEPLAPHARM in the transaction with a total volume of €550 million.

Latham & Watkins has advised CHEPLAPHARM AG (CHEPLAPHARM), a leading international platform for well-established branded medicines, on its agreement for a structured investment with global investment firms Atlantic Park and GIC, with a total volume of €550 million. The investment will be provided in the form of a subordinated convertible instrument and will mandatorily convert into ordinary shares of CHEPLAPHARM AG. Credit Suisse, Deutsche Bank, and J.P. Morgan acted as Joint Placement Agents to CHEPLAPHARM on this transaction.

The Latham team was led by Frankfurt partners Oliver Seiler and David Rath, with partner Rüdiger Malaun and associates Camilla Kehler-Weiß, Alexandre Maturana, Jan Penselin, and Isabel Willius. Advice was also provided on corporate matters by London partner Mike Turner and Frankfurt partner Maximilian Platzer, with Düsseldorf counsel Sebastian Goslar, Frankfurt associate Sönke Bock, and London associate Jon Fox; on finance matters by Frankfurt partner Alexandra Hagelüken, with counsel Cora Grannemann and associate Philipp Seltzer; on tax matters by Munich counsel Ulf Kieker, with associate Johannes Lieb; on antitrust matters by Frankfurt partner Max Hauser and Hamburg counsel Jana Dammann de Chapto. The team worked in close partnership with CHEPLAPHARM's in-house team led by Head of Legal Jan Klumb and Legal Counsel Anne Noltin.